Comparing Different Amounts of Vitamin D Supplementation to Preschool Children Living in Northern and Southern Sweden

NCT01741324 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2016-11-01

No results posted yet for this study

Summary

Vitamin D has a range of biological effects of public health relevance. Vitamin D status is assessed on levels of its metabolite 25-hydroxyvitamin D \[25(OH)D\], where levels \< 50 nmol/L indicate insufficiency. Despite studies indicating that the vitamin D intake among Swedish children are significantly below recommendations, little is known of their vitamin D status. The investigators have recently found inadequate vitamin D status in pre-school children living in northern Sweden, especially in dark-skinned children and during the winter months despite vitamin D intakes meeting the recommendations. Overall, 25% of the light skinned and 40% of the dark skinned children had S-25(OH) D \<50 nmol/L (Öhlund I, unpublished data). The aim is to examine which amount of vitamin D is needed to maintain or increase S-25(OH)D to ≥50 nmol/L among 97.5% of the participants regardless of skin color or geographic location (northern or southern Sweden). Furthermore the investigators will examine if vitamin D status affects on health markers as bone density, blood pressure, serum lipids, fatty acids, inflammatory and immunological markers and mental wellbeing.

Children aged 5-8 years living either northern (Umeå) or southern Sweden (Malmö) will be recruited to this trial during November-December 2012. They will be randomized to a vitamin D supplement of either 10 or 25 g per day, or in Malmö also placebo to be used for three months. The randomization will be stratified according to skin color (light or dark) according to a method using visual inspection and interviews of parents/guardians. The investigators will use a 2×2×2 factorial design to investigate the effects of two different doses of vitamin D (10 µg and 25 µg) in children with dark and light skin color, living in northern (Umeå) and southern (Malmö), Sweden. In order to achieve a moderate difference between groups (effect size 0.25) 20 children per group are required (power\> 87%, alpha = 0.05). With an estimated dropout of 10%, a total of 220 children will be included.

At baseline, the participants will undergo blood sampling for S-25(OH)D and other biomarkers, blood pressure and anthropometrical measurements, including bone densitometry and body composition using air displacement pletysmography, and the parents will answer a questionnaire on behavioral and emotional problems in the participating child using the Child Behavior Checklist. These measurements will be repeated at follow-up in February-March 2013.

Conditions

  • Vitamin D Deficiency

Interventions

DIETARY_SUPPLEMENT

Vitamin D 25 microg/d

The vitamin D supplement will be provided as a milk drink taken daily.

DIETARY_SUPPLEMENT

Vitamin D 10 microg/d

The vitamin D supplement will be provided as a milk drink taken daily.

DIETARY_SUPPLEMENT

No extra vitamin D

Milk drink with no extra vitamin D (placebo)

Sponsors & Collaborators

  • Region Skane

    collaborator OTHER
  • Umeå University

    lead OTHER

Principal Investigators

  • Inger Öhlund, Ph.D. · Umeå University

  • Torbjörn Lind, M.D., Ph.D. · Umeå University

  • Pia Karlsland-Åkesson, M.D., Ph.D. · University hospital, Malmö/Lund

  • Sven-Arne Silfverdal, M.D., Ph.D. · Umeå University

  • Olle Hernell, M.D., Ph.D. · Umeå University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
5 Years
Max Age
7 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2013-04-30
Completion
2013-07-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01741324 on ClinicalTrials.gov